Albemarle (ALB)
(Delayed Data from NYSE)
$127.59 USD
+4.64 (3.77%)
Updated May 24, 2024 04:00 PM ET
After-Market: $127.78 +0.19 (0.15%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum C VGM
Albemarle (ALB) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$161.58 | $300.00 | $81.00 | 31.42% |
Price Target
Based on short-term price targets offered by 24 analysts, the average price target for Albemarle comes to $161.58. The forecasts range from a low of $81.00 to a high of $300.00. The average price target represents an increase of 31.42% from the last closing price of $122.95.
Analyst Price Targets (24)
Broker Rating
Albemarle currently has an average brokerage recommendation (ABR) of 2.10 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 24 brokerage firms. The current ABR compares to an ABR of 1.97 a month ago based on 23 recommendations.
Of the 24 recommendations deriving the current ABR, 12 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 50% and 4.17% of all recommendations. A month ago, Strong Buy made up 56.52%, while Buy represented 4.35%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 12 | 13 | 13 | 10 | 10 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 9 | 8 | 7 | 10 | 9 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 2 | 2 | 2 | 2 | 2 |
ABR | 2.10 | 2.01 | 1.97 | 2.23 | 2.20 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/21/2024 | Scotiabank | Ben Isaacson | Strong Buy | Hold |
4/11/2024 | Berenberg Bank | Andres Castanos-Mollor | Hold | Strong Buy |
3/15/2024 | Loop Capital Markets | Christopher Kapsch | Strong Buy | Strong Buy |
3/11/2024 | Argus Research Corp. | William V Selesky | Not Available | Strong Buy |
3/8/2024 | Vertical Research Partners | Kevin W Mccarthy | Not Available | Hold |
3/7/2024 | KeyBanc Capital Markets | Aleksey Yefremov | Strong Buy | Strong Buy |
3/7/2024 | Mizuho SecuritiesUSA | John Roberts | Hold | Hold |
12/5/2023 | Piper Sandler | Charles N Neivert | Hold | Strong Sell |
11/7/2023 | BMO Capital Markets | Joel Jackson | Strong Buy | Strong Buy |
10/26/2023 | Robert W. Baird & Co. | Benjamin J Kallo | Strong Buy | Strong Buy |
9/8/2023 | Evercore Partners | Stephen Richardson | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.10 |
ABR (Last week) | 2.01 |
# of Recs in ABR | 24 |
Average Target Price | $161.58 |
LT Growth Rate | 16.00% |
Industry | Chemical - Diversified |
Industry Rank by ABR | 150 of 252 |
Current Quarter EPS Est: | 0.89 |